Amneal Executive VP reports sale of 33,436 AMRX shares at ~$9.05

Rhea-AI Filing Summary

Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported the sale of Class A common stock on 08/12/2025. The filing shows 33,436 shares were disposed in one or more transactions at a weighted average price of approximately $9.05 per share, with individual trade prices ranging from $9.05 to $9.07.

After these transactions, Boyer directly beneficially owns 256,670 shares. The Form 4 discloses no derivative transactions and includes a footnote stating the sales were executed in multiple transactions and that the reporting person will provide detailed per-price allocation upon request.

Positive

• Disclosure provided: The insider filed a Form 4 documenting the transaction, supporting regulatory transparency.
• Retained stake: The reporting person still directly owns 256,670 shares, showing continued ownership interest.

Negative

• Insider sale: 33,436 shares were sold, reducing the reporting person’s holdings.
• Marketable disposition: Sales occurred at a weighted average near $9.05, with prices ranging to $9.07.

Insights

Securities Analyst

TL;DR: Routine insider sale — 33,436 shares sold at about $9.05; retained direct stake 256,670 shares; no derivatives reported.

The Form 4 documents a straightforward disposition by an executive officer rather than an option exercise or derivative transaction. The sale size (33,436 shares) and the remaining direct ownership (256,670 shares) are explicit and the reported price range ($9.05–$9.07) is narrow, indicating execution over closely spaced trades. From a market-impact perspective, this filing is a routine disclosure of insider selling and does not, by itself, indicate material change to the company’s capital structure.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure: Form 4 reports multiple sales with weighted-average pricing and offers supplemental allocation details on request.

The filing meets Section 16 reporting requirements by documenting the transactions, ownership form (direct), and the post-transaction shareholdings. The footnote clarifies the sales occurred across multiple trades at prices between $9.05 and $9.07 and commits to provide per-trade allocations if requested, which supports transparency. No 10b5-1 plan or derivative activity is identified on the face of this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOYER ANDREW S

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/12/2025		S		33,436	D	$9.05(1)	256,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.05 to $9.07 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the AMRX Form 4 filed by Andrew S. Boyer report?

The Form 4 reports that Andrew S. Boyer, Executive Vice President, sold 33,436 shares of Amneal (AMRX) Class A common stock on 08/12/2025 and now directly owns 256,670 shares.

How many AMRX shares were sold and at what price?

The filing shows 33,436 shares were disposed at a weighted average price of about $9.05 per share; the footnote states individual trade prices ranged from $9.05 to $9.07.

Does the Form 4 show any derivative transactions for AMRX?

No. Table II for derivative securities is empty in this filing, so no derivative transactions were reported.

What is the reporting person’s relationship to Amneal (AMRX)?

The reporting person is listed as an Officer with the title Executive Vice President and the ownership is reported as direct.

Is there additional detail available about the per-trade allocation of the sale?

Yes. The footnote states the reporting person will provide to Amneal or the SEC, upon request, full information regarding the number of shares sold at each separate price within the stated range.